Shots:
Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials
She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…
Shots:
John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders
Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
Shots:
Johanna Contreras, Director of the Ambulatory Heart Failure Network & Diversity Mount Sinai Health System spoke about the initiation of this campaign and how it is empowering Latina women with heart failure to prioritize their heart health
Lupe, a woman diagnosed with heart failure, shared her experience of her life with heart failure and…
The 12th edition of the Pharma IPR Conference organized by Informa Markets will be held from 1-3 March 2023 in Mumbai. This is the only conference in India's pharmaceutical industry that focuses on Intellectual Property. The aim of this conference is to bring together all stakeholders in the pharma sector to discuss and deliberate on…
Weece Events is glad to invite you to attend the Global PHT Expo & Summit 2023 which is an International Conference & Exhibition on PHARMA, HEALTHCARE & TECHNOLOGY focusing on the Future of the Global Pharma & Healthcare Ecosystem in a digitally transforming world. The event is happening from 15-17th Feb 2023 at Hyatt Centric,…
Active Ingredient: Ibrutinib
Dosage Forms & Strengths:
Capsules: 70 mg and 140 mg
Tablets: 140 mg, 280 mg, 420 mg, and 560 mg
Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)
First Approval: US (13 Nov 2013), EU (Oct 2014)
Revenue Analysis
Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…
Shots:
Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis
The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment
The…
Telehealth has become a reality in modern times.
The new era of telehealth offers numerous benefits for patients and healthcare professionals alike.
With this new era becoming normal in our lives, pharmacists have a significant role to play.
They are key players in setting up telemedicine in healthcare and ensuring patients understand this advancement.
This guide will…
Virtue Insight is glad to invite you to attend the 31st Pharmacovigilance 2023 which is happening on 01-02 February 2023 at Radisson RED London Heathrow, UK. The focus will be on the latest developments in pharmacovigilance, drug safety & risk management.
With the increasing number of diseases and the non-medical use of prescription drugs, the…
Shots:
Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy
He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization
The interview shows up how Calliditas is…

